{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T04:22:59Z","timestamp":1745468579568,"version":"3.40.4"},"reference-count":16,"publisher":"S. Karger AG","issue":"1","license":[{"start":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T00:00:00Z","timestamp":1736294400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T00:00:00Z","timestamp":1736294400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Case Rep Oncol"],"abstract":"<jats:p>Introduction: The PCM1-JAK2 rearrangement is generated through the t(8; 9)(p22; p24) translocation event. The myeloid\/lymphoid neoplasms with eosinophilia (MLN-eo) with PCM1-JAK2 rearrangement is the common types of MLN-eo with tyrosine kinase fusion genes (MLN-Eo-tk). MLN-Eo with PCM1-JAK2 rearrangement is a rare disease with a poor prognosis and no unified treatment guidelines. The response of disease to ruxolitinib may be transient and it may only serve as a temporary treatment prior to transplantation. Case Presentation: We report 1 patient diagnosed with MLN-Eo with PCM1-JAK2 rearrangement who exhibited resistance to ruxolitinib, subsequently received pegylated interferon (Peg-IFN) and lenalidomide. The Peg-IFN was discontinued due to adverse effects; the patient has been receiving lenalidomide monotherapy for a duration exceeding 2 years, achieving complete hematologic remission and molecular response, significant amelioration of symptoms, as well as regression of hepatosplenomegaly. Conclusion: A case of MLN-Eo with PCM1-JAK2 rearrangement underwent continuous oral lenalidomide monotherapy for over 2 years. The patient achieved complete hematologic remission and molecular response during the long-term follow-up; however, a complete molecular remission was not attained. The underlying mechanism of lenalidomide in these diseases necessitates further comprehensive investigation through fundamental research and clinical trials. <\/jats:p>","DOI":"10.1159\/000542692","type":"journal-article","created":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T17:00:39Z","timestamp":1736355639000},"page":"190-197","source":"Crossref","is-referenced-by-count":0,"title":["A Case of Myeloproliferative Neoplasm with Eosinophilia Associated with PCM1-JAK2 Rearrangement"],"prefix":"10.1159","volume":"18","author":[{"given":"Wen","family":"Zhou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaojia","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhengdong","family":"Hao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Songlin","family":"Chu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liansheng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lijuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"127","published-online":{"date-parts":[[2025,1,8]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404104"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1200\/PO.19.00082"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-04-4263"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26966"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12963"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1093\/ajcp\/aqaa208"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1038\/s41379-018-0165-9"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-06-433821"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-015-2451-7"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-017-2994-x"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.753842"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1055\/s-0040-1709495"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.11406\/rinketsu.59.323"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2020.07.006"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1080\/17474086.2017.1366853"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2014.03.020"}],"container-title":["Case Reports in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/karger.com\/cro\/article-pdf\/18\/1\/190\/4320669\/000542692.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/karger.com\/cro\/article-pdf\/18\/1\/190\/4320669\/000542692.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T15:02:26Z","timestamp":1745420546000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000542692"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,8]]},"references-count":16,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,1,1]]}},"URL":"https:\/\/doi.org\/10.1159\/000542692","archive":["Portico"],"relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.6084\/m9.figshare.28163363","asserted-by":"subject"}]},"ISSN":["1662-6575"],"issn-type":[{"type":"electronic","value":"1662-6575"}],"subject":[],"published":{"date-parts":[[2025,1,8]]}}}